CRSP
Crispr Therapeutics AG
55.80$
-5.5%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | +1,990.7% | +693.9% | -92.4% | +9,169.8% | -99.8% | +126,893.2% | -100.0% | +84,762.4% | -90.5% | -90.0% | |
| – | +731.0% | +235.9% | +65.3% | +63.0% | +57.6% | +50.2% | -62.4% | +9.0% | +18.1% | -15.4% | +111.3% | |
| – | – | – | – | – | +9,169.8% | -192.8% | – | -112.0% | – | -131.4% | – | |
| – | +731.0% | +235.9% | +65.3% | +63.0% | +57.6% | +23.4% | +98.1% | +5.2% | -16.1% | -17.2% | -17.3% | |
| – | +162.1% | +131.7% | +15.4% | +34.7% | +31.5% | +35.1% | +19.9% | -0.3% | -25.7% | -4.2% | +0.8% | |
| – | +292.0% | +182.2% | +44.1% | +53.4% | +49.8% | -64.7% | +529.2% | +4.4% | -17.9% | -15.4% | -13.4% | |
| – | – | – | – | – | – | -858.3% | – | -280.2% | – | – | – | |
| – | – | +7,353.7% | -100.0% | – | – | -74.8% | +275.5% | +95.5% | – | – | – | |
| – | – | – | – | – | – | -617.1% | – | -271.4% | – | – | – | |
| – | – | +6,814.3% | +261.4% | -68.4% | -19.0% | +80.6% | +131.1% | -117.4% | – | +24.2% | +1.3% | |
| – | – | – | – | – | – | -621.8% | – | -272.2% | – | – | – | |
| – | – | – | – | – | – | -770.8% | – | -265.8% | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.